In damage control mode, Perrigo clarifies that it's off the hook in key Zantac case

Thursday, one of those generic manufacturers, Perrigo, issued a statement to clarify its status in the first case heard in the U.S.—George Bayer vs. Boehringer Ingelheim, et al.—in which the plaintiff moved this week for a voluntary dismissal after being hospitalized.